Induction and extended consolidation with daratumumab, cyclophosphamide, bortezomib, lenalidomide, and dexamethasone in patients with high-risk multiple myeloma (OPTIMUM/MUKnine): 5-year follow-up of a multicentre, externally controlled, phase 2 trial
Elsevier ·
Аннотация у издателя не опубликована — полный текст доступен по ссылке ниже.
Induction and extended consolidation with daratumumab, cyclophosphamide, bortezomib, lenalidomide, and dexamethasone in patients with high-risk multiple myeloma (OPTIMUM/MUKnine): 5-year follow-up of a multicentre, externally controlled, phase 2 trial. // The Lancet Oncology. – URL: https://www.sciencedirect.com/science/article/pii/S147020452600286X?dgcid=rss_sd_all
Induction and extended consolidation with daratumumab, cyclophosphamide, bortezomib, lenalidomide, and dexamethasone in patients with high-risk multiple myeloma (OPTIMUM/MUKnine): 5-year follow-up of a multicentre, externally controlled, phase 2 trial. The Lancet Oncology. https://www.sciencedirect.com/science/article/pii/S147020452600286X?dgcid=rss_sd_all
“Induction and extended consolidation with daratumumab, cyclophosphamide, bortezomib, lenalidomide, and dexamethasone in patients with high-risk multiple myeloma (OPTIMUM/MUKnine): 5-year follow-up of a multicentre, externally controlled, phase 2 trial.” The Lancet Oncology.
@article{article101615,
title = {Induction and extended consolidation with daratumumab, cyclophosphamide, bortezomib, lenalidomide, and dexamethasone in patients with high-risk multiple myeloma (OPTIMUM/MUKnine): 5-year follow-up of a multicentre, externally controlled, phase 2 trial},
journal = {The Lancet Oncology},
url = {https://www.sciencedirect.com/science/article/pii/S147020452600286X?dgcid=rss_sd_all}
}